ScholarIQanswers from OpenAlex
Synthetic Genomics (United States)
InstitutionResearch output, impact & collaborations
Synthetic Genomics (United States) is a institution indexed in ScholarIQ from OpenAlex.
What is known about Synthetic Genomics (United States)?
ScholarIQrecord summary
Synthetic Genomics (United States) is a research organisation in La Jolla, US. OpenAlex records 407 works and 59,902 citations for it. 252 researchers list it as their most recent affiliation.
How many works does Synthetic Genomics (United States) have?
ScholarIQindexed works
Synthetic Genomics (United States) has 407 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Synthetic Genomics (United States) have?
ScholarIQcitation count
Synthetic Genomics (United States) has 59,902 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Synthetic Genomics (United States)?
ScholarIQresearcher count
Synthetic Genomics (United States) has 252 researchers in the ScholarIQ index.
What is the average h-index at Synthetic Genomics (United States)?
ScholarIQavg h-index
Synthetic Genomics (United States) has an average h-index of 39 in OpenAlex.
What is the ROR of Synthetic Genomics (United States)?
ScholarIQror
The ROR for Synthetic Genomics (United States) is on the source record.
What is the OpenAlex record for Synthetic Genomics (United States)?
ScholarIQopenalex
The OpenAlex for Synthetic Genomics (United States) is on the source record.
Who are the most-cited researchers behind Synthetic Genomics (United States)?
ScholarIQtop researchers by citations
What are the most-cited papers on Synthetic Genomics (United States)?
ScholarIQmost cited works
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer, Fabrice Barlési, Daniel Waterkamp, Keunchil Park, Fortunato Ciardiello, Joachim von Pawel, Shirish M. Gadgeel, Toyoaki Hida, Dariusz M. Kowalski, Manuel Cobo, Diego Cortinovis, Joseph W. Leach, Jonathan Polikoff, Carlos H. Barrios, Fairooz F. Kabbinavar, Osvaldo Arén Frontera, Filippo de Marinis, Hande Turna, Jong-Seok Lee, Marcus Ballinger, Marcin Kowanetz, Pei He, Daniel S. Chen, Alan Sandler, David R. Gandara
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Louis Fehrenbacher, Alexander I. Spira, Marcus Ballinger, Marcin Kowanetz, Johan Vansteenkiste, Julien Mazières, Keunchil Park, David C. Smith, Á. Artal, C. Lewanski, Fadi Braiteh, Daniel Waterkamp, Pei He, Wei Zou, Daniel S. Chen, Jing Yi, Alan Sandler, Achim Rittmeyer
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F. McDermott, Mahrukh Huseni, Michael B. Atkins, Robert J. Motzer, Brian I. Rini, Bernard Escudier, Lawrence Fong, Richard W. Joseph, Sumanta K. Pal, James A. Reeves, Mario Sznol, John D. Hainsworth, W. Kimryn Rathmell, Walter M. Stadler, Thomas E. Hutson, Martin Gore, Alain Ravaud, Sergio Bracarda, Cristina Suárez, Riccardo Danielli, Viktor Gruenwald, Toni K. Choueiri, Dorothee Nickles, Suchit Jhunjhunwala, Elisabeth Piault‐Louis, Alpa Thobhani, Jiaheng Qiu, Daniel S. Chen, Priti S. Hegde, Christina Schiff, Gregg Fine, Thomas Powles
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)
Marcin Kowanetz, Wei Zou, Scott Gettinger, Hartmut Koeppen, Mark Kockx, Peter Schmid, Edward E. Kadel, Ignacio I. Wistuba, Jamie E. Chaft, Naiyer A. Rizvi, David R. Spigel, Alexander I. Spira, Fred R. Hirsch, Victor Cohen, Dustin Smith, Zach Boyd, Natasha Miley, Susan Flynn, Vincent Lévêque, David S. Shames, Marcus Ballinger, Simonetta Mocci, Geetha Shankar, Roel Funke, Garret M. Hampton, Alan Sandler, Lukas C. Amler, Ira Mellman, Daniel S. Chen, Priti S. Hegde
How much of the research on Synthetic Genomics (United States) is open access?
ScholarIQopen access share
75%OPEN ACCESS